DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06182891

CompletedPhase NA

Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

300

actual

Study population

Chronic kidney disease, Type 2 diabetes

Key I/E criterion

•UACR ≥30

Primary endpoints

•UACR, change•Evaluation of the biomarkers of the epithelial-mesenchymal transition process

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06182891
Org study IDXYFY2021-KL236-02

Timeline

Milestones

Study start2021-10-30actual
Primary completion2023-06-30actual
Study completion2023-10-30actual
Study first posted2023-12-27actual
Last update posted2023-12-27actual

Assets

Investigational agents

Dulaglutide

Study populations

Who this study enrolls

Chronic kidney diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•All adults aged 18 and above
•No minors involved in the study
•Diabetic Nephropathy defined as a urinary albumin-to-creatinine ratio ≥30 mg/g at least twice in three measurements within a period of 3-6 months

Exclusion criteria

•Patients with other types of kidney disease
•Urinary tract infection
•Type 1 diabetes

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Renal / kidney
3
Safety / tolerability / PK
1
Other (unclassified)
1

Renal / kidney

3 endpoints
Primary/protocol endpoint

Evaluation of the urinary albumin-to-creatinine ratio

Time frame:3,6 and 12 months after dulaglutide injection treatment

uACR, change

change from baseline, improvement

LOINC 9318-7

Secondary/protocol endpoint

Evaluation of the estimated glomerular filtration rate

Time frame:3,6 and 12 months after dulaglutide injection treatment

eGFR, change

change from baseline, improvement

LOINC 98979-8

Secondary/protocol endpoint

Evaluation of the cystatin C

Time frame:3,6 and 12 months after dulaglutide injection treatment

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Evaluation of adverse event

Time frame:3,6 and 12 months after dulaglutide injection treatment

Treatment-emergent AEs (any)

descriptive

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Evaluation of the biomarkers of the epithelial-mesenchymal transition process

Time frame:3,6 and 12 months after dulaglutide injection treatment

change from baseline, descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.